| Literature DB >> 35057145 |
Ashwini Naganthran1, Gayathiri Verasoundarapandian1, Farah Eryssa Khalid1, Mas Jaffri Masarudin2, Azham Zulkharnain3, Norazah Mohammad Nawawi4,5, Murni Karim6,7, Che Azurahanim Che Abdullah8,9, Siti Aqlima Ahmad1,10.
Abstract
Silver nanoparticles (AgNPs) have been employed in various fields of biotechnology due to their proven properties as an antibacterial, antiviral and antifungal agent. AgNPs are generally synthesized through chemical, physical and biological approaches involving a myriad of methods. As each approach confers unique advantages and challenges, a trends analysis of literature for the AgNPs synthesis using different types of synthesis were also reviewed through a bibliometric approach. A sum of 10,278 publications were analyzed on the annual numbers of publication relating to AgNPs and biological, chemical or physical synthesis from 2010 to 2020 using Microsoft Excel applied to the Scopus publication database. Furthermore, another bibliometric clustering and mapping software were used to study the occurrences of author keywords on the biomedical applications of biosynthesized AgNPs and a total collection of 224 documents were found, sourced from articles, reviews, book chapters, conference papers and reviews. AgNPs provides an excellent, dependable, and effective solution for seven major concerns: as antibacterial, antiviral, anticancer, bone healing, bone cement, dental applications and wound healing. In recent years, AgNPs have been employed in biomedical sector due to their antibacterial, antiviral and anticancer properties. This review discussed on the types of synthesis, how AgNPs are characterized and their applications in biomedical field.Entities:
Keywords: AgNPs; action mechanism; biological; biomedical applications; biomedical properties of AgNPs; chemical; design and synthesis methods of silver nanoparticles; physical
Year: 2022 PMID: 35057145 PMCID: PMC8779869 DOI: 10.3390/ma15020427
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Synthesis of AgNPs.
Figure 2Annual numbers of publications relating to the search terms “Silver nanoparticles” and “Biological/Chemical/Physical” in the Scopus publication database between 2010 and 2020 (English language only).
Figure 3Research trend clusters mapping. (a) Network visualization of author keywords co-occurrences (b) Network visualization of author’s keywords cluster analysis across the annual average publications on the biomedical applications of AgNPs published between 2010 and 2020. Abbreviations: Fourier-transform infrared spectroscopy (FTIR), Transmission electron microscopy (TEM), Scanning electron microscopy (SEM), and X-ray diffraction (XRD).
Figure 4The advantages and disadvantages of three types of synthesis (adapted from Mukherjee and Patra, [38], Simões et al. [39] and Xu et al. [4]).
Reported size and shape of AgNPs synthesized by microorganisms.
| Name of Bacteria | Size (nm) | Shape | References |
|---|---|---|---|
|
| 10–30 | spherical | [ |
| 45 ± 0.15 | spherical | [ | |
|
| 40–60 | multi-shaped | [ |
|
| 8–12 | spherical | [ |
|
| 20–50 | spherical | [ |
|
| 35 | spherical | [ |
|
| 80–101 | spherical | [ |
| Cyanobacterium | 3.30–17.97 | quasi-spherical | [ |
| Cyanobacteria | 5–26 | spherical | [ |
| 7–22 | spherical | [ | |
|
| 7–22 | spherical | [ |
|
| 26.84–44.42 | spherical | [ |
| 200 | Triangle, hexagon and spherical | [ | |
| 10–20 | spherical | [ | |
| 8–30 | spherical | [ | |
| 7–31 | spherical | [ | |
| 198–595 | spherical | [ | |
|
| 4.4 | spherical | [ |
| 38 | spherical | [ | |
| 13.84 ± 4.56 | spherical | [ | |
| 5–15 | cubical | [ |
Figure 5Biomolecules in flower extracts of Ixora coccinea involved in the synthesis of AgNPs.
Figure 6Overview of steps of synthesize mediated by plant or plant extract (adapted from Nadeem et al. [176]).
Figure 7Overview of steps of synthesize mediated by algae extract (adapted from Vincy et al. [202]).
Figure 8Methods of characterization of biosynthesized AgNPs.
Biogenic AgNPs characterization with XRD.
| Plants/Bacteria/Algae | Average Crystallite Size (nm) | AgNPs Peaks at 2θ Angles | References |
|---|---|---|---|
| 45 ± 0.15 nm | 38.44°, 44.38°, 56.77°, 64.38° and 77.50° | [ | |
| 20–30 nm | 38.45°, 46.35°, 64.75° and 78.05° | [ | |
| 179.3 nm, 90.38 nm and 80.28 nm | 38.22°, 44.42°, 64.56° and 77.50° | [ | |
| 42 nm (leaf) and 44 nm (extract) | 32.5°, 38.3°, 44.4°, 64.6°, and 76.8° and 32.4°, 38.3°, 44.5°, 64.5°, and 76.7° | [ | |
| ~28.19 nm | 24.934°, 37.0359° and 43.8572° | [ | |
| 30–50 nm | 38.15°, 44.25°, 64.47°, 77.38° and 81.64° | [ | |
| 10–50 nm | 37.2°, 43.4°, 63.5° and 76.6° | [ | |
| 21 nm | 37.88°, 44.31°, 64.34° and 77.39° | [ | |
| Brown seaweed | 54–85 nm | 11.58°, 32.04°, 37.89° and 46.96° | [ |
Figure 9Applications of AgNPs in Biomedical Applications.
Figure 10Formation of biofilm and AgNPs application (adapted from [245]).
Figure 11The possible mechanism (ROS activation) towards gram-positive and gram-negative (adapted from Pandey et al. [248]).
In-vitro testing against human pathogens.
| Organism | Source | Size and Shape | Test Organism | References |
|---|---|---|---|---|
| Bacteria | Spherical; 30–40 nm |
| [ | |
| Bacteria | Spherical; 102 nm | [ | ||
| Plant | Spherical; 16 nm | [ | ||
| Marine | Bacteria | Spherical; 3–22 nm | [ | |
|
| Plant | Spherical; 38 ± 2 nm | [ | |
|
| Plant | Spherical; 20–35 nm | [ | |
|
| Fungus | Quasi-spherical; 2–20 nm |
| [ |
| Plant | Spherical; 5–50 nm |
| [ | |
|
| Plant | Spherical; 8 nm | [ | |
|
| Algae | Spherical and few triangular; 5–25 nm |
| [ |
| Algae | Spherical; 5–50 nm |
| [ | |
| Fungus | Spherical; 52.26 nm | [ | ||
|
| Fungus | Spherical; 1–10 nm | [ | |
| Alga | Algae | Spherical, Triangle, Pseudo-spherical, rectangle; 5–50 nm |
| [ |
|
| Plant | Spherical; 20–60 nm | [ |
Figure 12The antiviral activities of AgNPs [273].
The antiviral properties of biogenic AgNPs.
| Virus | Family | Source of AgNPs | Size of AgNPs | Mechanism | References |
|---|---|---|---|---|---|
| Herpes simplex virus type 1 and type 2 (HSV-1 & HSV-2) |
| 4–31 nm | Block interaction of viral cells | [ | |
| Human parainfluenza virus type 3 (HPIV3) |
| ||||
| Zika virus |
|
| 20–40 nm | Penetrate the infectious agent | [ |
| Dengue virus (DEN-2) |
|
| 30–70 nm | Inhibitory effect on viral RNA synthesis | [ |
| 10–35 nm | Inhibition of viral replication | [ | |||
| 7–22 nm | Capping facilitated surface activity makes these AgNPs a tool for vector control | [ | |||
| HSV-1, HAV-10 and CoxB4 virus |
|
| 10.12–27.89 nm | Interact with herpes simplex thymidine kinase, hepatitis A 3c proteinase and Coxsackie virus B4 3c protease | [ |
|
| 8.91–14.48 nm | Interact with herpes simplex thymidine kinase, hepatitis A 3c proteinase and Coxsackie virus B4 3c protease | [ | ||
| Respiratory Syncytial Virus (RSV) |
|
| 0.23 nm | Prevent the virus from entering cells and inhibition of viral replication | [ |
| HIV-1 |
|
| 12–28 nm | HIV-1 reverse transcriptase inhibitory activity | [ |
| Herpes Simplex Virus (HSV-I,II) |
|
| - | Prevent the virus from entering cells | [ |
The anticancer results of green synthesized AgNPs.
| Organism | Source of AgNPs | Cancer Cell Line | IC50 Value | Size and Shape of AgNPs | References |
|---|---|---|---|---|---|
| Mixture of | Plant | HT-29 | 150 μg/mL | Spherical; 20–51 nm | [ |
|
| Plant | MCF-7 | 30 μg/mL | Spherical; 12.5–41.9 nm | [ |
|
| Fungus | MCF-7 | 25.24 ± 0.990 μg/mL | Spherical; 25 nm | [ |
|
| Fungus | MCF-7 | 2.46 μg/mL | Varying in sizes | [ |
|
| Fungus | MCF-7 | 50 μg/mL | Spherical; 8–20 nm | [ |
|
| Bacteria | MCF-7 | 50 μg/mL | Spherical; 83–176 nm | [ |
|
| Plant | PC3 | 10 μg/mL | Cubical; 9–32 nm | [ |
|
| Plant | HeLA, SiHa | Dose dependent | Spherical; 40 ± 1.2 nm | [ |
|
| Plant | A5449 | 5 μg/mL | Spherical; 6–45 nm | [ |
|
| Plant | HeLa, PANC-1 | 31.5 μg/mL, 84 μg/mL | Spherical, circular, rectangular; 62–103 nm (TEM) | [ |
|
| Plant | HeLa | 100 μg/mL | 46.1 nm | [ |
|
| Plant | MCF-7 | 12.35 μg/mL | Spherical;10–60 nm | [ |
|
| Plant | PC3 | 6.85 μg/mL | Spherical; 30–50 nm | [ |
|
| Bacteria | MCF-7, HCT-116 | 6.147 μg/mL, 5.369 μg/mL | Quasi-spherical; 3.30–17.97 nm | [ |
|
| Fungus | EAC, HT-29 | 2.15 μg/mL, 2 μg/mL | Spherical; 5–50 nm | [ |